CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 60 enrolled
Drug / intervention
Norepinephrinedrug
Likely dose
Norepinephrine 0.02 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06574555
NCT06574555Phase 4Completed

Determination of the 90% Effective Dose of the Initial Bolus of Norepinephrine in Elective Cesarean Section: An Up-Down Study

Pontificia Universidad Catolica de Chile·interventional·Posted Aug 28, 2024·Updated Aug 29, 2025

In Brief

A Phase 4 clinical trial evaluating Norepinephrine for Hypotension and 4 related conditions. Completed, enrolled 60 participants across 1 site.

Detailed Summary

The investigators are aiming to determine what is the effective intravenous dose required of an initial bolus of norepinephrine prior to a maintenance infusion to prevent a 20% decrease in maternal blood pressure from baseline following the administration of spinal anesthesia for elective cesarean section in healthy parturients

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChile
Collaborators--

Timeline

Phase 4CompletedFinished
20252026
First PostedAug 28, 2024
Enrollment StartApr 1, 2025
Primary CompletionAug 1, 2025
Study CompletionAug 2, 2025
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 1.8 years ago

Interventions

Norepinephrinedrug

The outcome of patient n in each sequence will determine the dose to be allocated patient n+1. Successive doses will be determined with the up-and-down k-in-row design method for ED90 determination: * Failure: the dose should be increased in one level (+0.02 µg/kg) after failure to respond (arterial hypotension); * Success: decrease in one level (-0.02 µg/kg) upon successful response (no arterial hypotension), but only after observing at least k-consecutive positive responses at the same dose (in this case, k=7); otherwise, remain at the same dose. This will be done until each sequence completes n=30.